To highlight a potential role played by CK2 in resistant CML cell lines, we focused our attention on the two Bcr-Abl downstream survival pathways MEK/ERK1/2 and PI3K/Akt/mTOR [2, 3], which are also under the control of CK2 at different levels [20–23] (see Figure 8). Here, AKT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.